Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryAug202013	Fate Therapeutics Files Registration Statement for Proposed Initial Public Offering San Diego, CA – Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to Read All »	View HTML Fate Therapeutics Files Registration Statement for Proposed Initial Public Offering 11.2 KB
Toggle SummaryDec132022	Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic Models SAN DIEGO , Dec. 13, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML
Toggle SummaryApr082010	Fate Therapeutics Expands Stem Cell Modulator Pipeline with Acquisition of Verio Therapeutics San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Read All »	View HTML Fate Therapeutics Expands Stem Cell Modulator Pipeline with Acquisition of Verio Therapeutics 12.6 KB
Toggle SummaryMay112010	Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announces the appointment of six respected research leaders to the Company’s Scientific Advisory Board (SAB). The new SAB members bring deep experience and expertise in systems biology, epigenetics, gene regulation, expression Read All »	View HTML Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline 12 KB
Toggle SummaryMar032015	Fate Therapeutics Expands and Strengthens Leadership Team SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Wendy Levin, M.D., M.S. Read All »	View HTML Fate Therapeutics Expands and Strengthens Leadership Team 14.6 KB
Toggle SummaryJun052015	Fate Therapeutics Enters Into Sponsored Research Agreement With Boston Children's Hospital to Develop Immunoregulatory Cell Therapy for Treatment of Autoimmune Diseases Proof-of-Concept Data in Well-Established Model of Type 1 Diabetes Presented Today at the 75th Scientific Sessions of the American Diabetes Association Read All »	View HTML Fate Therapeutics Enters Into Sponsored Research Agreement With Boston Children's Hospital to Develop Immunoregulatory Cell Therapy for Treatment of Autoimmune Diseases 23.7 KB
Toggle SummarySep132018	Fate Therapeutics Enters into Exclusive License Agreement with Gladstone Institutes for CRISPR-based Cellular Reprogramming New Approach Uses CRISPR-mediated Genome Activation for iPSC Generation SAN DIEGO , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune Read All »	View HTML
Toggle SummaryMar122014	Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies First Patient Enrolled in PUMA Study Approved for Conduct at Ten Leading U.S. Centers Interim Data Expected in 2H14 SAN DIEGO, March 12, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators Read All »	View HTML Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies 18.6 KB
Toggle SummaryNov162009	Fate Therapeutics Closes $30 Million Series B Financing Led by OVP Venture Partners and Includes Syndicate of Corporate Investors Read All »	View HTML Led by OVP Venture Partners and Includes Syndicate of Corporate Investors 12.1 KB
Toggle SummaryAug042021	Fate Therapeutics Appoints Yuan Xu to its Board of Directors SAN DIEGO , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu , Ph.D., to its Board of Directors as an Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.